Literature DB >> 30381263

Hotspot enumeration of CD8+ tumor-infiltrating lymphocytes using digital image analysis in triple-negative breast cancer yields consistent results.

Patrick J McIntire1, Elaine Zhong2, Ami Patel2, Francesca Khani2, Timothy M D'Alfonso3, Zhengming Chen4, Sandra J Shin5, Paula S Ginter2.   

Abstract

Tumor-infiltrating lymphocytes (TILs) have emerged as prognostic in triple-negative breast cancer (TNBC). We aimed to assess the consistency of hotspot placement and TIL enumeration among multiple pathologists. Additionally, we assessed hotspot TIL count consistency by comparing hotspot counts in 3 separate locations within a single whole-tissue section. Anti-CD8 immunohistochemistry was performed on a representative section from 66 cases of primary TNBC, which were then scanned as whole-slide images. Quantification of the tissue area and combined stromal and intratumoral CD8+ TILs was performed using digital image analysis (DIA) within 2.2 mm-diameter circle hotspots. TIL counts were quantified as absolute counts and densities (absolute count/tissue area in micrometers2). For each case, 6 pathologists placed a single hotspot, defined as an area with the subjectively highest CD8+ immunoreactivity, within the tumor bed. Separately for each case, a single pathologist placed hotspots in 3 different locations within a single tumor section. Intraclass correlation coefficients (ICCs) were generated following TIL enumeration via DIA. ICCs for single hotspot placement by 6 pathologists were 0.96 for density and 0.97 for absolute counts, respectively. In 32% of cases (21/66), all the hotspots placed by the 6 pathologists were in the same location. When evaluating hotspots in 3 different locations within a tumor, the ICC was 0.95 for both density and absolute counts. Hotspot evaluation by DIA is a reproducible method for CD8+ TIL quantification, and the use of hotspots may reduce TIL count variation caused by intratumoral TIL heterogeneity.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD8; DIA; Hotspots; TILs; TNBC

Mesh:

Year:  2018        PMID: 30381263     DOI: 10.1016/j.humpath.2018.10.014

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

1.  Open radial artery harvesting better preserves endothelial function compared to the endoscopic approach.

Authors:  Mario F Gaudino; Roberto Lorusso; Lucas B Ohmes; Navneet Narula; Patrick McIntire; Antonella Gargiulo; Maria Rosaria Bucci; Jeremy Leonard; Mohamed Rahouma; Antonino Di Franco; Guo-Wei He; Leonard N Girardi; Robert F Tranbaugh; Annarita Di Lorenzo
Journal:  Interact Cardiovasc Thorac Surg       Date:  2019-10-01

2.  PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.

Authors:  Katherine D Gray; Jaclyn E McCloskey; Yogindra Vedvyas; Olivia R Kalloo; Steve El Eshaky; Yanping Yang; Enda Shevlin; Marjan Zaman; Timothy M Ullmann; Heng Liang; Dessislava Stefanova; Paul J Christos; Theresa Scognamiglio; Andrew B Tassler; Rasa Zarnegar; Thomas J Fahey; Moonsoo M Jin; Irene M Min
Journal:  Clin Cancer Res       Date:  2020-09-04       Impact factor: 12.531

3.  TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients.

Authors:  Maya Dadiani; Daniela Necula; Smadar Kahana-Edwin; Nino Oren; Tamir Baram; Irina Marin; Dana Morzaev-Sulzbach; Anya Pavlovski; Nora Balint-Lahat; Liat Anafi; Stefan Wiemann; Cindy Korner; Einav Nili Gal-Yam; Camila Avivi; Bella Kaufman; Iris Barshack; Adit Ben-Baruch
Journal:  Cancer Immunol Immunother       Date:  2020-03-20       Impact factor: 6.968

4.  Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model.

Authors:  Alvaro Ruiz-Martinez; Chang Gong; Hanwen Wang; Richard J Sové; Haoyang Mi; Holly Kimko; Aleksander S Popel
Journal:  PLoS Comput Biol       Date:  2022-07-22       Impact factor: 4.779

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.